Mutations of FLT3 receptor affect its surface glycosylation, intracellular localization, and downstream signaling
Open Access
- 1 January 2020
- journal article
- review article
- Published by Elsevier in Leukemia Research Reports
- Vol. 13, 100187
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Education, Culture, Sports, Science and Technology
- Astellas Pharma
- Pfizer
This publication has 51 references indexed in Scilit:
- Fluvastatin inhibits FLT3 glycosylation in human and murine cells and prolongs survival of mice with FLT3/ITD leukemiaBlood, 2012
- Current findings for recurring mutations in acute myeloid leukemiaJournal of Hematology & Oncology, 2011
- Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implicationsJournal of Hematology & Oncology, 2011
- Molecular Imaging of N-linked Glycosylation Suggests Glycan Biosynthesis Is a Novel Target for Cancer TherapyClinical Cancer Research, 2010
- KIT Mutations Induce Intracellular Retention and Activation of an Immature Form of the KIT Protein in Gastrointestinal Stromal TumorsClinical Cancer Research, 2008
- Abnormal Localization and Accumulation of FLT3-ITD, a Mutant Receptor Tyrosine Kinase Involved in LeukemogenesisCells Tissues Organs, 2008
- FLT-3: a new focus in the understanding of acute leukemiaThe International Journal of Biochemistry & Cell Biology, 2005
- Tyrosine Phosphorylation Regulates Maturation of Receptor Tyrosine KinasesMolecular and Cellular Biology, 2005
- The role of FLT3 in haematopoietic malignanciesNature Reviews Cancer, 2003
- Pharmacology of competitive inhibitors of HMg-CoA reductasePharmacological Research, 1995